Table 1.

Demographic and other information included in the current study.

	Hospitalized n=18	Mild n=14	Pre-2020 HC n=103	(−)rRT-PCR n=13	p
Female (%)	7 (39%)	6 (43%)	61 (59.2%)	9 (69%)	0.434
Age, median (range), yr	61.5† (30–81)	31.5† (26–81)	62 (24–87)	35.8 (29–63)	<0.0001
Race					<0.0001
Asian	2 (11%)	0	2 (2%)	1 (8%)
African American	13 (72%)†	0†	15 (14%)	3 (23%)
Non-Hispanic Caucasian	3 (17%)	12 (86%)	82 (80%)	8 (61%)
Hispanic	0	1 (7%)	0	1 (8%)
Other	0	1 (7%)	4 (4%)	0
Inpatient/outpatient*	18/0	1/13	-	0/13	<0.001
Days since symptom onset, median (range)*	10.5 (4–24)	18.5 (9–33)	-	17 (2–43)	0.057*
Respiratory failure requiring intubation (%)	14 (78%)	0	-	0	<0.001
Duration of disease, median (range), days	10.5 (4–24)	11 (4–23)†	-	4.5 (1–30)	0.126
Clinical symptoms*
Cough	16 (89%)	9 (64.3%)	-	6 (46%)	0.036
Fever/chills	15 (83%)	10 (71%)	-	5 (38%)	0.030
Shortness of breath	13 (72%)	6 (43%)	-	3 (23%)	0.022
Myalgia	6 (33%)	9 (64%)	-	4 (31%)	0.130
Headaches	5 (28%)	8 (57%)	-	2 (15%)	0.058
Sore throat	2 (11%)	6 (43%)	-	5 (38%)	0.096
Nasal congestion/rhinorrhea	2 (11%)	6 (43%)	-	4 (31%)	0.121
Diarrhea	2 (11%)	3 (21%)	-	3 (23%)	0.630
Anosmia	0†	6 (43%)†	-	0	<0.001
Fatigue	1 (6%)	2 (14%)	-	2 (15%)	0.623
Vomiting	0	1 (7%)	-	0	0.323
Never symptomatic*	0	0	-	3 (23%)	0.021
SARS-CoV-2 detected by rRT-PCR*	16/16	9/9	-	0/13	<0.001
Anti-S1-RBD IgG, median (range), OD	2.04† (0.15–2.73)	0.37† (0.08–2.09)	0.12 (0.01–2.09)	0.28 (0.02–0.91)	<0.001
Anti-S1 IgM, median (range) OD	1.91 (0.31–2.95)	2.12 (0.98–2.78)	1.14 (0.33–2.53)	2.07 (0.25–3.36)	<0.001
Anti-E IgM, median (range), OD	2.23 (1.03–3.04)	2.26 (1.28–3.67)	1.52 (0.15–3.04)	2.58 (0.46–3.10)	<0.001

Categorical and continuous variables which differed between groups are shown in bold.

^*Comparison between symptomatic, recovered, and (−)rRT-PCR groups only.

^†Different between hospitalized and mild cases at p<0.005.

^††n=8 for mild and n=10 for (−)rRT-PCR.